• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Karyopharm - oncology





























Blame the BOD and our big institutional holders for not vetting out our current CEO and CCO.

Neither held their current positions prior.

So let me get this straight...they roll MK only to bring in equally unqualified people in key positions like CEO and CCO? How does that make any sense?
 








Blame the BOD and our big institutional holders for not vetting out our current CEO and CCO.

Neither held their current positions prior.

So let me get this straight...they roll MK only to bring in equally unqualified people in key positions like CEO and CCO? How does that make any sense?

Paulson is garbage.